2015
DOI: 10.3109/14397595.2015.1091155
|View full text |Cite
|
Sign up to set email alerts
|

Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52

Abstract: Patients with different anti-ARS in combination with anti-Ro52 appear to be associated with distinctive clinical subsets.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

6
33
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 41 publications
(42 citation statements)
references
References 29 publications
6
33
3
Order By: Relevance
“…Our results confirm the frequencies of anti‐Mi2 and anti‐SAE antibodies, respectively, in 8.5% and 5.1% and are close to previous findings, respectively, in 9% (meta‐analysis) and 1% to 9% . In accordance with previous large series, we did not identify specific clinical features of DM and the risk of cancer or ILD in the presence of anti‐Mi2 or anti‐SAE antibodies …”
Section: Discussionsupporting
confidence: 92%
See 4 more Smart Citations
“…Our results confirm the frequencies of anti‐Mi2 and anti‐SAE antibodies, respectively, in 8.5% and 5.1% and are close to previous findings, respectively, in 9% (meta‐analysis) and 1% to 9% . In accordance with previous large series, we did not identify specific clinical features of DM and the risk of cancer or ILD in the presence of anti‐Mi2 or anti‐SAE antibodies …”
Section: Discussionsupporting
confidence: 92%
“…This might be due to our exclusive dermatological recruitment of patients as the presenting clinical features of the “antisynthetase syndrome” are myositis, ILD and arthritis, while cutaneous manifestations are mostly limited to Raynaud's phenomenon and mechanic's hands . Our results are in concordance with the data from previous studies reporting a significantly lower risk of eyelid involvement and, more globally, a less inflammatory cutaneous phenotype in patients DM with anti‐ARS antibodies …”
Section: Discussionsupporting
confidence: 91%
See 3 more Smart Citations